In combination with estimates of GBA mutation prevalence, this large-scale, relatively unbiased study suggests that up to 10% of Parkinson’s disease patients carry known genetic variants that could be targeted by new drug therapies in clinical trials and future treatment. This evidence concerns the gene GBA1 and Parkinson disease.